Hepatic fibrosis is a necessary stage for the development of chronic liver disease to cirrhosis and hepatocellular carcinoma. The mortality rate of end-stage cirrhosis is extremely high, and delaying the development of hepatic fibrosis or compensated-stage cirrhosis to decompensate is an effective way to control liver disease. However, no specific anti-hepatic fibrosis drugs have appeared yet and to develop new drugs is urgent. Our previous study found that octanordammarane 7C that derived from the Chinese herb Radix Paeoniae Rubra can inhibit the proliferation and activation of hepatic stellate cells, and it can also improve the fibrosis induced by BDL in rats significantly. At the same time, we found that the expression of carboxylesterase 1 (CES1) in hepatic stellate cells was reduced by 7C. Based on this originality and according to the reduction effect of compound 7C on CES1, we would explore the role of CES1 in the development of hepatic fibrosis by in vitro overexpression, hepatic cirrhosis tissue microarray and knockout mice. At the same time, to elucidate the mechanism of compound 7C regulation on CES1 expression. Finally, we aim at to prove our hypothesis that compound 7C inhibits the activation of hepatic stellate cells and exerts its anti-hepatic fibrosis effect through repressing the expression of CES1.
肝纤维化是慢性肝病发展到肝硬化、肝癌的必经阶段,终末期肝硬化患者的致死率极高,延缓肝纤维化或肝硬化代偿阶段向失代偿阶段发展是控制肝病恶化的有效途径。但目前还未上市针对性治疗肝纤维化的药物,新药物的开发迫在眉睫。我们前期研究发现,来源于中药赤芍的降八碳达玛烷类化合物7C能够抑制肝星状细胞的增殖和活化,明显改善BDL诱导的大鼠肝纤维化,并且化合物7C能够降低肝星状细胞中羧酸酯酶1(CES1)的表达。本项目拟在此原创性基础上,以化合物7C降低CES1的表达为依据,通过体外过表达、肝硬化组织芯片、基因敲除小鼠等手段深入研究CES1在肝纤维化发生发展中的作用,同时阐明化合物7C调控CES1表达的分子机制。最终验证化合物7C通过下调CES1的表达,抑制肝星状细胞的活化,从而发挥其抗肝纤维化作用的假说。
肝纤维化作为各类慢性肝病进展至肝衰竭或肝癌的必经之路,阻止或延缓其发展,可以从源头上减少对移植肝的需求。面对全球数量庞大的肝硬化及非酒精性脂肪性肝病(NASH)患者,并没有针对性的药物被批准,所以对病理可逆的肝纤维化阶段进行详细的机制研究及药物开发十分必要。本研究中,我们发现拥有自主知识产权的新型小分子化合物7C在BDL模型和CDAHFD模型中,给药后可以显著降低大小鼠血清转氨酶水平,起到减轻肝脏损伤的作用。并且7C在抑制肝纤维化发展的同时,还具有改善脂质变性的作用,对于NASH合并肝纤维化患者具有极大的治疗优势。深入的机制研究发现,7C可以上调法尼醇X受体(FXR)通路的活性,发挥其对纤维化的抑制作用;7C还可以激活自噬通路,降解肝脏中过多的脂质,改善脂肪变性。总之,7C可能通过FXR和自噬,减轻脂质和纤维化,共同发挥其对NASH-肝纤维化的改善作用。另外,目前我们的研究已证实了羧酸酯酶1(CES1)在人肝星状细胞活化中的激活作用,其在小鼠中的作用正在通过基因敲除小鼠来验证。
{{i.achievement_title}}
数据更新时间:2023-05-31
涡度相关技术及其在陆地生态系统通量研究中的应用
Intensive photocatalytic activity enhancement of Bi5O7I via coupling with band structure and content adjustable BiOBrxI1-x
Asymmetric Synthesis of (S)-14-Methyl-1-octadecene, the Sex Pheromone of the Peach Leafminer Moth
七羟基异黄酮通过 Id1 影响结直肠癌细胞增殖
宁南山区植被恢复模式对土壤主要酶活性、微生物多样性及土壤养分的影响
白藜芦醇抗肝纤维化作用新靶标及分子机制研究
FXR/FASN双靶点化合物的设计、合成和抗肝纤维化活性研究
土家药四楞麻抗肝纤维化活性成分及作用机制研究
贵州苗族“消疤草”抗肝纤维化的活性成分及作用机制研究